Oncimmune Holdings plc (LON: ONC), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announced the appointment of Dr. Parag Mallick to its Scientific Board.
Dr Parag Mallick is an Associate Professor of Radiology at Stanford University. He is a member of the Canary Center for Cancer Early Detection. Originally trained as an engineer and biochemist, his research spans computational and experimental systems biology, cancer biology and nanotechnology. He received his BS in Computer Science and Biochemistry at Washington University in St. Louis and then went onto complete his doctoral studies with David Eisenberg at UCLA. After his PhD, he trained with Prof Dr Ruedi Aebersold in clinical proteomics and systems biology at the Institute for Systems Biology.
Dr Mallick’s research at the Mallick Lab is focused on pioneering approaches for using big data, mathematical modelling and machine learning to discover cancer biomarkers and enable personalised and predictive medicine.
Dr Adam M Hill, CEO of Oncimmune Holdings commented:
“Parag’s work is prodigious in the field of the early detection of cancer using a number of complementary tools and processes. His mission and expertise will be invaluable to Oncimmune as we continue to develop our immunogenic protein platform and high throughput discovery approach, as well as consider the value of contextual data in clinical testing.”
Professor Peter Johnston, Chair of the Scientific Board commented:
“I’m pleased to welcome Parag as the latest member of Oncimmune’s Scientific Board. Oncimmune has assembled a team of high quality individuals who all share Oncimmune’s belief that early detection is the key to beating cancer and helping healthcare systems cope with the burdens of many diseases. The calibre of the individuals participating on this Scientific Board is an excellent validation of the potential of Oncimmune’s immunogenic protein platform and we are excited by what Oncimmune can achieve in the next three years and beyond.”
Dr Parag Mallick commented:
“I believe the future of early cancer detection lies in the identification of biomarkers which can not only be used to detect cancers earlier, but also to describe how they are likely to behave. Whilst there are thousands of publications highlighting putative candidates, very few biomarkers are being used clinically. Oncimmune has already developed a panel of biomarkers for the early detection of lung cancer and liver cancer and I am looking forward to working closely with the other Scientific Board members and the Company as it embarks on its next stage of growth.”